Article

Meningococcal conjugate vaccines: optimizing global impact

Epidemic Intelligence Service, Division of Applied Sciences, Scientific Education and Professional Development Program Office.
Infection and Drug Resistance 09/2011; 4:161-9. DOI: 10.2147/IDR.S21545
Source: PubMed

ABSTRACT Meningococcal conjugate vaccines have several advantages over polysaccharide vaccines, including the ability to induce greater antibody persistence, avidity, immunologic memory, and herd immunity. Since 1999, meningococcal conjugate vaccine programs have been established across the globe. Many of these vaccination programs have resulted in significant decline in meningococcal disease in several countries. Recent introduction of serogroup A conjugate vaccine in Africa offers the potential to eliminate meningococcal disease as a public health problem in Africa. However, the duration of immune response and the development of widespread herd immunity in the population remain important questions for meningococcal vaccine programs. Because of the unique epidemiology of meningococcal disease around the world, the optimal vaccination strategy for long-term disease prevention will vary by country.

0 Followers
 · 
155 Views
  • Source
    MENİNGOKOK ENFEKSİYONLARI TANI, TEDAVİ VE KORUNMA, Edited by Prof. Dr. Mehmet Ceyhan, 01/2013: chapter 4CMenB MENİNGOKOKAL GRUP B AŞISI (rDNA, KOMPONENT, ADSORBE), NOVARTİS;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The study compared the immunogenicity of two lots of the meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) differing in serogroup A polysaccharide (PS) O-acetylation levels, and evaluated immunogenicity and safety compared to a licensed ACWY polysaccharide vaccine (Men-PS).In this phase III, partially-blinded, controlled study, 1170 healthy subjects aged 18-25 years were randomized (1:1:1) to receive one dose of MenACWY-TT Lot A (ACWY-A; 68% O-acetylation), Lot B (ACWY-B; 92% O-acetylation) or Men-PS (82% O-acetylation). Immunogenicity was evaluated in terms of serum bactericidal activity using rabbit complement (rSBA). Solicited symptoms, unsolicited adverse events (AEs) and serious AEs (SAEs) were recorded.Immunogenicity, in terms of rSBA geometric mean titers, was comparable for both lots of MenACWY-TT. Vaccine response rates across serogroups were 79.1-97.0% in both ACWY groups, and 73.7-94.1% in the Men-PS group. All subjects achieved rSBA titers ≥1:8 for all serogroups. All subjects in both ACWY groups and 99.5-100% in the Men-PS group achieved rSBA titers ≥1:128. Pain was the most common solicited local symptom, reported more frequently in the ACWY (53.9-54.7%) than in the Men-PS (36.8%) groups. The most common solicited general symptoms were fatigue and headache, reported by 28.6-30.3% and 26.9-31.0% of subjects, respectively. Two subjects reported SAEs; one was considered related to vaccination (blighted ovum; ACWY-B group).The level of serogroup A PS O-acetylation did not impact vaccine immunogenicity. MenACWY-TT (Lot A) was non-inferior to Men-PS in terms of vaccine response and was well tolerated.This study is registered at www.clinicaltrials.gov NCT01154088.
    Clinical and vaccine Immunology: CVI 07/2013; 20(10). DOI:10.1128/CVI.00162-13 · 2.37 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Quantitative determination of the individual polysaccharide components in multivalent meningococcal vaccines is an important step in manufacturing and regulatory control. Current methods are complicated due to the use of multiple chromatographic setups and/or other analytical techniques for the four meningococcal serogroup polysaccharides (A, C, Y, W135). In addition, different methods are sometimes used depending on whether or not the polysaccharide is conjugated to a carrier protein. In an effort to simplify such analyses, hydrolysis conditions were determined for the optimal yield of each characteristic saccharide from the respective repeating units. One condition was identified for mannosamine-6-phosphate from MenA, one for neuraminic acid from MenC, and one for both glucose and galactose from MenY and MenW135, respectively. These conditions, initially assessed for monovalent solutions, were then confirmed for a quadrivalent solution. The monosaccharide products were separated, identified and quantitated using a single HPAEC-PAD protocol, with a customised multi-stage linear gradient eluent profile and one column setup, for determination of all four serogroup components. Comparison to calibration curves constructed from sets of monosaccharide or hydrolysed polysaccharide standards allowed for the quantitation of each characteristic serogroup monosaccharide in polysaccharide and polysaccharide-conjugate vaccines. When required, molecular size separation using a non-cellulosic centrifugal filter device effectively removed all interfering saccharide excipient without loss of serogroup polysaccharides. These methods were used to analyse multiple lots of a number of different monovalent or multivalent real polysaccharide-based vaccine products, in liquid or lyophilised powder formulations, with or without excipients. The methods were demonstrated to be highly reproducible and very useful for the evaluation of antigen content and lot-to-lot consistency of manufacture. The methods described here represent an increase in precision, level of accuracy and efficiency compared to current methods, and may be adaptable for evaluation of other types of polysaccharide-based vaccines.
    Vaccine 06/2013; 31(36). DOI:10.1016/j.vaccine.2013.05.098 · 3.49 Impact Factor

Preview

Download
1 Download
Available from